Pfizer's Message To Wall Street: We're Doing Things Differently Now

Three months after closing Pfizer's $68 billion acquisition of Wyeth (1"The Pink Sheet" DAILY, Jan. 26, 2009), Pfizer has already integrated both companies' R&D organizations and is now working to achieve steady, predictable, but diversified growth, CEO Jeff Kindler said at a Goldman Sachs health care conference Jan. 6